MEDP vs RGC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Medpace exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptional ROE of 70.23%. However, the stock is trading at a significant premium to its Graham Number ($73.6) and is currently priced above its growth-based intrinsic value of $438.96. While revenue and earnings growth remain robust with a consistent track record of beats, aggressive insider selling and a low current ratio (0.74) introduce notable risk. The current price of $514.90 exceeds the analyst target of $500.08, suggesting the stock is currently overextended.
Regencell Bioscience (RGC) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 3/9, placing it in the 'Weak' health category. The company is currently trading at an astronomical Price-to-Book ratio of 2867.00, indicating a massive disconnect between market price and tangible asset value. With 0% profit margins and a negative ROE of -54.81%, the company lacks the operational efficiency to justify its $14.18B market capitalization. Despite historical price surges, the current technical trend is 0/100 (Bearish), suggesting a speculative bubble that has lost momentum.
Compare Another Pair
Related Comparisons
MEDP vs RGC: Head-to-Head Comparison
This page compares Medpace Holdings, Inc. (MEDP) and Regencell Bioscience Holdings Limited (RGC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.